Kathleen Moore to Chemotherapy, Adjuvant
This is a "connection" page, showing publications Kathleen Moore has written about Chemotherapy, Adjuvant.
Connection Strength
0.698
-
Adjuvant chemotherapy for the "oldest old" ovarian cancer patients: can we anticipate toxicity-related treatment failure in a vulnerable population? Cancer. 2009 Apr 01; 115(7):1472-80.
Score: 0.308
-
Contribution of age to clinical trial enrollment and tolerance with ovarian cancer. Gynecol Oncol. 2017 04; 145(1):32-36.
Score: 0.132
-
Ovarian cancer in the octogenarian: does the paradigm of aggressive cytoreductive surgery and chemotherapy still apply? Gynecol Oncol. 2008 Aug; 110(2):133-9.
Score: 0.073
-
Serous fallopian tube carcinoma: a retrospective, multi-institutional case-control comparison to serous adenocarcinoma of the ovary. Gynecol Oncol. 2007 Dec; 107(3):398-403.
Score: 0.070
-
Clinical analysis of pathologic complete responders in advanced-stage ovarian cancer. Gynecol Oncol. 2022 04; 165(1):82-89.
Score: 0.047
-
Factors influencing clinical trial enrollment among ovarian cancer patients. Gynecol Oncol. 2017 09; 146(3):465-469.
Score: 0.034
-
Evaluation of the efficacy and toxicity profile associated with intraperitoneal chemotherapy use in older women. Gynecol Oncol. 2017 08; 146(2):268-272.
Score: 0.034